Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications

Journal of Population Therapeutics and Clinical Pharmacology

Volumn 21, Issue 3, 2014, Pages e357-e369

  Guertin, Jason ^a   LeLorier, Jacques ^a   Durand, Madeleine ^a   Gow, Robert ^b   Holbrook, Anne ^c,d   Levine, Mitchell ^c,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

ADHD; Amphetamine; Atomoxetine; Cardiovascular events; Methylphenidate; Reimbursement policy

Indexed keywords

AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE; AMPHETAMINE DERIVATIVE; CENTRAL STIMULANT AGENT; PROPYLAMINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG PROGRAM; FEMALE; HEALTH SERVICE; HOSPITALIZATION; HUMAN; ICD-10; ICD-9; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; ADOLESCENT; AMBULATORY CARE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CANADA; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG COST; ECONOMICS; EMERGENCY HEALTH SERVICE; HEALTH CARE DELIVERY; HEALTH INSURANCE; PROGRAM EVALUATION; PSYCHOLOGY; REIMBURSEMENT; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

ADOLESCENT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DRUG COSTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH SERVICES ACCESSIBILITY; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; METHYLPHENIDATE; ODDS RATIO; OFFICE VISITS; PROGRAM EVALUATION; PROPYLAMINES; QUEBEC; RISK ASSESSMENT; RISK FACTORS;

EID: 84908133651     PISSN: 17106222     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation May 6 2008;117(18):2407-23.
2. Romano E, Baillargeon RH, Tremblay RE. Prevalence of Hyperactivity-Impulsivity and Inattention Among Canadian Children: Findings from the First Data Collection Cycle (1994-1995) of the National Longitudinal Survey of Children and Youth. Hull: Human Resources Development Canada;2002.
3. Zuvekas SH, Vitiello B. Stimulant medication use in children: A 12-year perspective. Am J Psychiatry 2012;169:160-6.
4. Centers for Disease Control and Prevention. Increasing Prevalence of Parent-Reported Attention-Deficit/Hyperactivity Disorder Among Children - United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010;59:1439-43.
5. Wilens TE, Biederman J, Lerner M, Concerta Study G. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol Feb 2004;24(1):36-41.
6. Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. The Journal of Pediatrics. Sep 2005;147(3):348-54.
7. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry Aug 2006;45(8):919-27.
8. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. The Journal of Clinical Psychiatry Feb 2005;66(2):253-9.
9. Hammerness PG, Surman CB, Chilton A. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. Current Psychiatry Reports Oct 2011;13(5):357-63.
10. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf Oct 1 2010;33(10):821-42.
11. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med Apr 6 2006;354(14):1445-8.
12. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics Dec 2007;120(6):e1494-501.
13. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. The American Journal of Psychiatry Sep 2009;166(9):992-1001.
14. Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012;345:e4627.
15. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365:1896-904.
16. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009;32(11):1089-96.
17. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics Jun 2011;127(6):1102-10.
18. Bilan démographique du Québec: Institut de la statistique du Québec; December 2010.
19. Blais C, Lambert L, Hamel D, et al. Évaluation des soins et surveillance des maladies cardiovasculaires: Pouvons-nous faire confiance aux données médico-administratives hospitalières? Montreal: Institut national d'excellence en santé et en services sociaux (INESSS);2012.
20. Lambert L, Blais C, Hamel D, et al. Evaluation of care and surveillance of cardiovascular disease: Can we trust medico-administrative hospital data? Cdn J Cardiology 2012;28(2):162-8.
21. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol Aug 1995;48(8):999-1009.
22. Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol Feb 2000;53(2):183-94.
23. th 2012.
24. Morrow RL, Garland EJ, Wright JM, Maclure M, Taylor S, Dormuth CR. Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. CMAJ 2012 Apr 17;184(7):755-62.
25. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. American Journal of Epidemiology Nov 1 2003;158(9):915-20.
26. Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Medical care Oct 2007;45(10 Supl 2):S131-42.